Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA's PRIME: Helpful But Not A Panacea

Executive Summary

European Medicines Agency will try "just as hard" to aid companies who tap into other EU regulatory tools aimed at fostering quicker reviews, official says at BIA/MHRA conference.

You may also be interested in...



First EU PRIME Designations Go To Biogen, ChemoCentryx, Kite, NovImmune

The first four drugs European Medicines Agency selects for its new priority review program include Biogen's Alzheimer's disease treatment aducanumab. Fourteen applicants did not garner PRIME status.

Many PRIME Applicants Are Missing Pediatric Investigation Plans

Aside from pediatrics research issue, most of the first batch of applications for the new priority review scheme were "in scope," with numerous therapeutic areas targeted.

EMA's New PRIME Scheme Gets 18 Applications In First Month

Eleven applications to the European priority review program came from smaller companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel